Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

• Published in: British journal of cancer Vol. 93; no. 1; pp. 23 - 28
• Main Authors: Lim, S-T, Wong, E-H, Chuah, K-L, Leong, S-S, Lim, W-T, Tay, M-H, Toh, C-K, Tan, E-H
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.07.2005; Nature Publishing Group
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Non-Small-Cell Lung - drug therapy; Clinical Study; Cohort Studies; Drug Resistance; Epidemiology; Female; Gefitinib; Humans; Logistic Models; Lung cancer; Lung Neoplasms - drug therapy; Male; Medical sciences; Middle Aged; Molecular Medicine; Oncology; Pneumology; Proportional Hazards Models; Quinazolines - therapeutic use; Retrospective Studies; Smoking; Survival Analysis; Tumors; Tumors of the respiratory system and mediastinum; never-smoker; gefitinib; non-small-cell lung cancer; Antineoplastic agent; Human; Lung disease; Asiatic; Respiratory disease; Enzyme; Transferases; Lung cancer; Enzyme inhibitor; Malignant tumor; non-small cell lung carcinoma; Epidermal growth factor receptor; Non smoker; Cancerology; Efficiency; Smoker; Bronchus disease; Gefitinib; Protein-tyrosine kinase

We retrospectively analysed the results of patients with advanced non-small-cell lung cancer treated with gefitinib to derive clinical factors predictive of response and a favourable survival outcome. Patients were treated with gefitinib 250 mg per day and re-evaluated 4–8 weeks later with repeat CT...